De Novo Pharmaceuticals licenses Skelgen to Lilly
In silico drug design company De Novo Pharmaceuticals, of Cambridge in the UK, has entered into a licensing agreement with Eli Lilly under which De Novo will license its proprietary algorithm-based platform SkelGen on a non-exclusive basis for research on undisclosed targets belonging to Eli Lilly.
In silico drug design company De Novo Pharmaceuticals, of Cambridge in the UK, has entered into a licensing agreement with Eli Lilly under which De Novo will license its proprietary algorithm-based platform SkelGen on a non-exclusive basis for research on undisclosed targets belonging to Eli Lilly.
'This is the second major pharmaceutical company to recognise the value that SkelGen can deliver to their drug discovery process following our initial deal with Roche,' said Drs Bart Wuurman, ceo of De Novo. 'This agreement is precisely in line with our recently announced strategy of extending the commercial de-velopment and partnering of our computational chemistry platforms.'